Radial

Radial operates at the intersection of specialty mental healthcare, interventional psychiatry, and clinical technology. Its model differs from a purely virtual behavioral-health platform by combining in-person treatment locations with virtual care, insurance navigation, psychiatric services, therapy, and newer interventions such as TMS and Spravato®. It also differs from a standalone device manufacturer because it delivers treatment directly through a clinician network and is building an operating layer around brain medicine. The acquisition of Mindful Health Solutions gives Radial a larger delivery footprint and more than 100 clinicians, while the Evoke platform relationship adds objective brain-function data to its care infrastructure. Its practical competitive set likely includes specialty TMS and ketamine providers, integrated behavioral-health clinics, and virtual psychiatry companies, but Radial’s differentiator is the combination of clinic operations, evidence-based fast-acting treatments, clinical research, and technology-enabled care coordination. The main strategic challenge is demonstrating consistent outcomes and efficient unit economics across a geographically expanding network.

Radial has followed a rapid expansion path since its 2023 founding. It raised $7,797,992 in a seed round announced on Apr 29, 2024, then secured a $50 million Series A led by General Catalyst on Dec 9, 2025. A further $3 million Series A investment led by Brainsway was announced on Jul 20, 2026, bringing cumulative funding to $60,797,992 across three recorded rounds. The clearest operating inflection point came on Aug 20, 2026, when Radial acquired Mindful Health Solutions and expanded to a reported 27 clinics and more than 100 clinicians. This shifted the company from building an individual treatment platform toward operating a scaled clinical network. September 2026 technology announcements involving Firefly Neuroscience indicate a parallel effort to add objective brain-function measurement and non-drug device options to the care model. Radial has also stated that it plans to expand nationally during 2026, including its clinic network and technology partnerships. The trajectory is therefore driven by three reinforcing levers: capital deployment, acquisitions that add clinical capacity, and integration of specialized technologies. Execution risk includes maintaining care quality, clinician utilization, and regulatory compliance as the network grows.